New Treatment Strategies in Aggressive B-Cell Lymphomas: Advances, Application, and a Glimpse of the Future

Download these slides from a live symposium to gain more insight into the management of MCL.

Julie M. Vose, MD, MBA
Program Director Released: June 5, 2022

Download these slides from a live symposium to gain more insight into the frontline management of DLBCL.

Grzegorz Nowakowski, MD Released: June 5, 2022

Download these slides from a live symposium to gain more insight into the selection and sequencing of therapies in relapsed/refractory DLBCL.

Jeremy S. Abramson, MD, MMSc Released: June 5, 2022

Download this online resource developed to serve as a helpful guide for healthcare professionals on antibody–drug conjugates for aggressive B-cell lymphomas.

Download this online resource developed to serve as a helpful guide for healthcare professionals on bispecific antibodies for aggressive B-cell lymphomas.

Download this online resource developed to serve as a helpful guide for healthcare professionals on BTK inhibitors for aggressive B-cell lymphomas.

Download this online resource developed to serve as a helpful guide for healthcare professionals on CAR T-cell therapies for aggressive B-cell lymphomas.

Download this online resource developed to serve as a helpful guide for healthcare professionals on immunomodulatory agents and immune checkpoint inhibitors for aggressive B-cell lymphomas.

Download this online resource developed for healthcare professionals with a helpful guide for antibody-based therapies for aggressive B-cell lymphomas.

Download this online resource developed to serve as a helpful guide for healthcare professionals on XPO1 and nuclear export inhibitors for aggressive B-cell lymphomas.

In this on-demand webcast from a live symposium, oncology Julie M. Vose, MD, MBA; Jeremy S. Abramson, MD, MMSc; and Grzegorz S. Nowakowski, MD discuss the recent and evolving treatment strategies in the management of patients with aggressive B-cell lymphomas.

Julie M. Vose, MD, MBA
Program Director Jeremy S. Abramson, MD, MMSc Grzegorz Nowakowski, MD Physicians: maximum of 1.5 AMA PRA Category 1 Credits™ Released: June 8, 2022 Expired: No longer available for credit

In this commentary, expert faculty address frequently asked questions about incorporating novel and emerging treatment combinations into the management of MCL and DLBCL.

Julie M. Vose, MD, MBA
Program Director Jeremy S. Abramson, MD, MMSc Grzegorz Nowakowski, MD Released: July 28, 2022